MDLN
HealthcareMedline Inc. · Medical - Instruments & Supplies · $31B
What is Medline Inc.?
Medline Inc. is a large-cap healthcare company that manufactures and distributes medical-surgical products across hospitals, surgery centers, physician offices, and post-acute care facilities in the United States and internationally.
Medline operates through two segments. The Medline Brand segment manufactures and procures products across surgical solutions, front-line care, and laboratory and diagnostics. The Supply Chain Solutions segment distributes third-party national-brand products and provides logistics services. Revenue is generated by supplying healthcare facilities with everything from wound care and exam gloves to surgical procedure trays, orthopedic implants, and point-of-care diagnostic tools.
Medline Inc. is headquartered in Northfield, Illinois.
- Surgical procedure trays, drapes, gowns, and sterile wraps
- Wound care, exam gloves, and infection control products
- Point-of-care testing and laboratory diagnostics
- Durable medical equipment and patient plastics
- Third-party supply chain distribution and logistics
Is MDLN a Good Stock to Buy?
UQS Score rates MDLN as Below Average overall.
Among the five pillars, Valuation comes in at a Neutral rating — meaning the stock is not obviously expensive relative to its fundamentals, which may offer some comfort to investors weighing entry points in the med-surg distribution space.
Quality, Moat, Growth, and Risk all carry Weak ratings, reflecting broad structural challenges across profitability, competitive positioning, expansion trajectory, and balance-sheet durability.
Pro members can view the exact pillar breakdown and full financial metrics behind each rating at uqs-score.com. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MDLN pay dividends?
No — Medline Inc. does not currently pay a dividend.
Medline does not currently pay a dividend. As a capital-intensive manufacturer and distributor operating in a competitive healthcare supply market, the company appears to prioritize reinvestment in operations and supply chain infrastructure over returning cash to shareholders through distributions.
When does MDLN report earnings?
Medline Inc. reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Given the Weak ratings across Growth and Quality pillars, recent results appear to reflect ongoing pressure on margins and top-line expansion. Investors should weigh these signals against the broader med-surg distribution environment.
For the most current quarterly results, visit Medline Inc.'s official investor relations page.
MDLN Price History
+13.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
MDLN Long-term Outlook
The UQS pillar profile for MDLN points to a cautious fundamental outlook. Weak Growth and Risk ratings suggest limited near-term expansion visibility and meaningful balance-sheet or operational headwinds. The Neutral Valuation rating indicates the market has not yet priced in a significant premium, which could reflect muted expectations rather than a clear opportunity.
Growth drivers
- Expansion of supply chain distribution services to new healthcare facility types
- Growing demand for infection control and front-line care products in post-acute settings
- International market penetration for med-surg and diagnostic product lines
Key risks
- Weak Moat rating signals limited pricing power against larger or more specialized competitors
- Weak Risk rating points to potential leverage or operational vulnerability
- Commoditized product categories in med-surg distribution compress margins over time
MDLN vs Peers
Medline competes in the broader medical products and distribution landscape alongside several well-established healthcare companies.
Alcon focuses on eye care devices and surgical equipment, occupying a more specialized niche than Medline's broad med-surg distribution model.
ResMed concentrates on respiratory care and sleep disorder devices, giving it a narrower but highly recurring revenue base compared to Medline's diversified product catalog.
Becton Dickinson is a global medical technology giant with deep diagnostic and medication management capabilities, competing with Medline across several product categories at significant scale.
Frequently Asked Questions
What does Medline Inc. do?
Medline manufactures and distributes medical-surgical products to hospitals, surgery centers, physician offices, and post-acute care facilities. Its two segments cover branded product manufacturing — spanning surgical, front-line care, and diagnostics — and a supply chain distribution arm that handles third-party national-brand products.
Does MDLN pay dividends?
No, Medline does not currently pay a dividend. The company operates in a capital-intensive distribution environment and appears to direct resources toward operational reinvestment rather than shareholder distributions.
When does MDLN report earnings?
Medline reports on a quarterly cadence. Specific upcoming dates are not covered by our data source — check Medline's investor relations page for the most current earnings schedule.
Is MDLN a good stock to buy?
UQS Score rates MDLN as Below Average, with Weak ratings across Quality, Moat, Growth, and Risk pillars. Only Valuation registers as Neutral. Investors should weigh these signals carefully. The full pillar breakdown is available to Pro members at uqs-score.com.
Is MDLN overvalued?
The UQS Valuation pillar for MDLN is rated Neutral, suggesting the stock is neither obviously expensive nor deeply discounted relative to its fundamentals. Given the weakness in other pillars, the Neutral valuation may reflect limited market enthusiasm rather than a hidden opportunity.
How does MDLN compare to its competitors?
Compared to peers like Becton Dickinson and Alcon, Medline operates with a broader but less specialized product mix. Its Weak Moat rating suggests it faces meaningful competitive pressure from larger players with stronger brand recognition, proprietary technology, or deeper clinical relationships.
What is MDLN's market cap bracket?
Medline Inc. is classified as a large-cap company, placing it among the larger publicly traded healthcare manufacturers and distributors by market value.
Who founded Medline Inc.?
Medline has a long operating history as a private company before its public listing. Detailed founding information is widely available through public sources and the company's own corporate history disclosures.
Is MDLN a long-term quality indicator?
As a long-term quality indicator, MDLN's UQS profile raises concerns. Weak ratings across four of five pillars — Quality, Moat, Growth, and Risk — suggest the business faces structural challenges that could weigh on compounding potential over time. Pro members can access the complete analysis.
What is the main competitive advantage of Medline Inc.?
Medline's scale in med-surg distribution and its integrated manufacturing-plus-logistics model provide some operational breadth. However, the UQS Moat pillar rates this advantage as Weak, indicating that differentiation versus peers remains limited in the current competitive landscape.
What sector does MDLN belong to?
Medline Inc. operates in the Healthcare sector, specifically within medical-surgical product manufacturing and supply chain distribution. It serves a wide range of care settings, from acute hospital environments to post-acute and outpatient facilities.
Is MDLN a growth stock or value stock?
Based on UQS pillar labels, MDLN does not fit neatly into either category. The Growth pillar is rated Weak, limiting its growth-stock appeal, while the Neutral Valuation rating does not signal a deep-value opportunity. It currently sits in an uncertain middle ground.
Unlock Full MDLN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓See the exact UQS pillar scores for MDLN
- ✓View full financial metrics and trend data
- ✓Compare MDLN against sector peers side by side
- ✓Access the complete Quality and Risk breakdown
- ✓Screen for stronger alternatives in Healthcare
- ✓Get the full analyst-style report for Pro members
Pro Analysis
MDLN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 39.6 | 33.1 | 35.0 | 40.2 | 38.8 | 58.2 | +0.6 |
| May 7, 2026 | 39.0 | 34.3 | 35.0 | 38.7 | 37.9 | 54.9 | +0.3 |
| Apr 26, 2026 | 38.7 | 34.3 | 35.0 | 38.7 | 37.9 | 53.2 | +0.5 |
| Apr 19, 2026 | 38.2 | 34.3 | 35.0 | 38.7 | 37.9 | 49.8 | -0.5 |
| Apr 18, 2026 | 38.7 | 34.7 | 35.0 | 38.7 | 37.9 | 52.2 | +0.2 |
| Apr 14, 2026 | 38.5 | 34.7 | 35.0 | 38.7 | 37.9 | 50.6 | -0.2 |
| Apr 12, 2026 | 38.7 | 34.7 | 35.0 | 38.7 | 37.9 | 52.0 | -0.2 |
| Apr 11, 2026 | 38.9 | 34.7 | 35.0 | 38.7 | 37.9 | 53.5 | -0.1 |
| Apr 10, 2026 | 39.0 | 35.0 | 35.0 | 38.7 | 37.9 | 53.5 | -0.2 |
| Apr 9, 2026 | 39.2 | 35.0 | 35.0 | 39.0 | 37.9 | 54.7 | -0.1 |
MDLN — Pillar Breakdown
Quality
— 33.1/100 (25%)Medline Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 40.2/100 (20%)Medline Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 38.8/100 (15%)Medline Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 58.4/100 (15%)Medline Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 35/100 (25%)Medline Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MDLN.
Score Composition
Financial Data
More Stock Analysis
How is the MDLN UQS Score Calculated?
The UQS (Unified Quality Score) for Medline Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Medline Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Medline Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.